XRAY:NGS-DENTSPLY SIRONA Inc. (USD)

EQUITY | Medical Instruments & Supplies | Nasdaq Global Select

Last Closing

USD 14.93

Change

0.00 (0.00)%

Market Cap

USD 13.82B

Volume

2.44M

Analyst Target

USD 48.77
Analyst Rating

Verdict

ducovest Verdict
Created with Highstock 5.0.6

Verdict

About

Dentsply Sirona Inc is a designer, developer, manufacturer and marketer of consumable dental products for the professional dental market. The Company also manufactures and markets other consumable medical device products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
XRAY QQQ
  • QQQ
Relative Returns (From:    To: 2025-03-30 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ISRG Intuitive Surgical Inc

N/A

USD 203.97B
COO The Cooper Companies, Inc. Com..

N/A

USD 17.00B
HOLX Hologic Inc

N/A

USD 13.84B
ALGN Align Technology Inc

N/A

USD 13.76B
RGEN Repligen Corporation

N/A

USD 7.49B
MMSI Merit Medical Systems Inc

N/A

USD 6.12B
ICUI ICU Medical Inc

N/A

USD 3.59B
AZTA Azenta Inc

N/A

USD 1.99B
LMAT LeMaitre Vascular Inc

N/A

USD 1.93B
ATRC AtriCure Inc

N/A

USD 1.70B

ETFs Containing XRAY

HBD:CA BetaPro Gold Bullion 2x D.. 6.53 % 1.52 %

N/A

CAD 1.54M
HND:CA BetaPro Natural Gas 2x Da.. 6.04 % 1.52 %

N/A

CAD 0.19B
MVUS:SW 3.32 % 0.00 %

N/A

N/A
SPMV:SW 3.32 % 0.00 %

N/A

N/A
SQLV Royce Quant Small-Cap Qua.. 0.00 % 0.60 %

N/A

USD 0.03B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -21.34% 38% F 30% F
Dividend Return 0.84% 100% F 58% F
Total Return -20.50% 38% F 30% F
Trailing 12 Months  
Capital Gain -55.02% 21% F 19% F
Dividend Return 1.45% 75% C 33% F
Total Return -53.57% 21% F 19% F
Trailing 5 Years  
Capital Gain -61.55% 30% F 20% F
Dividend Return 6.26% 50% F 13% F
Total Return -55.29% 30% F 21% F
Average Annual (5 Year Horizon)  
Capital Gain -11.66% 19% F 5% F
Dividend Return -10.53% 19% F 5% F
Total Return 1.12% 67% D+ 26% F
Risk Return Profile  
Volatility (Standard Deviation) 31.19% 71% C- 32% F
Risk Adjusted Return -33.77% 14% F 8% B-
Market Capitalization 13.82B 82% B 85% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Instruments & Supplies) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 30.90 62% 42%
Price/Book Ratio 1.70 74% 52%
Price / Cash Flow Ratio 7.14 53% 36%
Price/Free Cash Flow Ratio 25.40 25% 14%
Management Effectiveness  
Return on Equity -34.75% 48% 37%
Return on Invested Capital -17.98% 45% 35%
Return on Assets 1.87% 73% 72%
Debt to Equity Ratio 81.67% 10% 27%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector